The Food and Drug Administration (FDA) announced its crackdown on dangerous stem cell clinics. In light of its new proposal, the FDA still maintains its pledge to ease the path to approval for companies and doctors with legitimate treatments in the growing field of stem cell clinics and research.
“The F.D.A.’s proposal is clear evidence of the fact that the regenerative medicine sector has matured and has moved from just a research sector to a development of market ready products,” said Partner Michael Werner.
Please note that email communications to the firm through this website do not create an attorney-client relationship between you and the firm. Do not send any privileged or confidential information to the firm through this website. Click "accept" below to confirm that you have read and understand this notice.